Lenz Therapeutics, INC Form 4 insider transactions

LENZ Therapeutics, Inc. Director James W. McCollum was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.

LENZ Therapeutics, Inc. Director Zachary Scheiner was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026, though he disclaims beneficial ownership as they are held for RA Capital entities.

Shawn Olsson, Chief Commercial Officer of Lenz Therapeutics, exercised stock options and acquired 1,400 shares of common stock at a price of $2.08 on April 9, 2025.

Evert B. Schimmelpennink, CEO of Lenz Therapeutics, exercised stock options to acquire 4,200 shares of common stock at $1.04 per share on March 7, 2025.

Shawn Olsson, Chief Commercial Officer of Lenz Therapeutics, was granted stock options to purchase 80,100 shares of common stock.

Marc Odrich, Chief Medical Officer of Lenz Therapeutics, receives stock options according to a Form 4 filing.

Lenz Therapeutics' Chief Financial Officer, Daniel R. Chevallard, was granted stock options for 70,444 shares, vesting over time, according to a recent SEC Form 4 filing.

Lenz Therapeutics CEO, Evert Schimmelpennink, was granted stock options for 279,100 shares, vesting over a period of time.

Chief Commercial Officer of Lenz Therapeutics, Shawn Olsson, exercised stock options to acquire 3,333 shares of common stock at $2.08 per share.

Evert B. Schimmelpennink, CEO of Lenz Therapeutics, exercises stock options and reports changes in beneficial ownership.

Daniel R. Chevallard, CFO of Lenz Therapeutics, acquired 3,188 shares of common stock on May 14, 2024.

Director James McCollum increased his holdings in Lenz Therapeutics by purchasing 31,332 shares of common stock at an average price of $15.993 on May 13, 2024.

RA Capital Management and related entities report changes in beneficial ownership of LENZ Therapeutics stock and warrants following the merger with LENZ Therapeutics Operations, Inc.

Shelley B Thunen, a director of Lenz Therapeutics, acquired 27,000 stock options on March 21, 2024, exercisable at $15.05, according to a recent SEC filing.

Director James W. McCollum reports acquiring shares and a warrant in LENZ Therapeutics following the closing of a merger and a private placement.

Frederic Guerard, a director of Lenz Therapeutics, acquired stock options as a result of the merger with LENZ Therapeutics Operations, Inc.

Director Zachary Scheiner acquired stock options for LENZ Therapeutics, though disclaims beneficial ownership due to an arrangement with RA Capital Management.

Kimberlee C. Drapkin, a director of LENZ Therapeutics, acquired stock options for 27,000 shares of common stock on March 21, 2024.

Director Jeffrey P. George acquired 27,000 stock options in Lenz Therapeutics, Inc. on March 21, 2024.

Daniel R. Chevallard, CFO of Lenz Therapeutics, acquired 200,000 stock options on March 21, 2024, according to a Form 4 filing with the SEC.

Chief Commercial Officer Shawn Olsson acquired stock options in Lenz Therapeutics following the merger with Generate Merger Sub, Inc.

Chief Medical Officer of Lenz Therapeutics, Marc Odrich, reports acquiring shares and stock options as a result of the merger with LENZ OpCo.

Evert B. Schimmelpennink, CEO of Lenz Therapeutics, acquired stock options as part of the merger agreement with Generate Merger Sub, Inc.

Versant Venture Capital reports changes in beneficial ownership of LENZ Therapeutics stock following a merger and reverse stock split.

Graphite Bio declares a special cash dividend of approximately $1.03 per share for stockholders in connection with its proposed merger with Lenz Therapeutics, pending stockholder approval and merger completion.

Graphite Bio provides supplemental disclosures related to its proposed merger with Lenz Therapeutics in response to stockholder complaints and demand letters alleging misrepresentations and omissions in the preliminary proxy statement/prospectus.